GLP-1 Weight Loss Calculator

Estimate how much you could lose on each GLP-1.

By GLP Index editorial Updated July 16, 2026
lbs

You could lose about

46 lbs

down to about 174 lbs (~21%)

Trial range (most people)

33–55 lbs

What this calculator estimates

This tool projects your potential weight loss on each GLP-1 by applying that drug’s average clinical-trial result to your current weight. It’s the fastest way to see the difference between the medications in real pounds — not just abstract percentages — and to set a realistic expectation before you start.

The key word is average. Every number here comes from a large clinical trial, and in those trials some people lost dramatically more than the average while others lost relatively little. Your result sits somewhere in a range, which is why the calculator shows a band, not just a single figure.

The trial numbers behind it

Each medication’s estimate is anchored to its main study:

MedicationAverage lossTrial
Zepbound (tirzepatide 15 mg)~21%SURMOUNT-1, 72 weeks
Wegovy (semaglutide 2.4 mg)~15%STEP 1, 68 weeks
Saxenda (liraglutide 3 mg)~8%SCALE, 56 weeks
Mounjaro* (tirzepatide)~21%same molecule as Zepbound
Ozempic* (semaglutide)~6%diabetes-dose trials

* Mounjaro, Ozempic, Rybelsus, Victoza, and Trulicity are FDA-approved for type 2 diabetes, not weight loss. Their figures are approximate — drawn from diabetes trials or the same-molecule obesity trial — and shown for education only.

Two things stand out. First, tirzepatide (Zepbound/Mounjaro) leads the pack — its ~21% average is territory that used to require surgery. Second, the same molecule can show very different numbers: Wegovy and Ozempic are both semaglutide, but Wegovy’s higher obesity-trial dose produces roughly double Ozempic’s diabetes-trial average.

Why your real result will differ

A calculator can’t know your biology, so treat the output as a reasonable expectation, not a promise. The biggest factors that move you within (or beyond) the range:

  • Dose reached. The trial averages assume you titrate up to and stay at the studied maintenance dose. People who stop climbing early tend to lose less.
  • Time. These results unfold over 12–18 months, not weeks. The early months are dose-ramp months.
  • Diet, protein, activity, and sleep. The trials paired the drug with lifestyle support for a reason — the medication works best as a floor for your appetite, not a replacement for the basics. Protecting muscle with enough protein also shapes how good the loss looks and feels.
  • Consistency and staying on it. Trial extensions show much of the weight returns after stopping, so durability depends on maintenance.

Using it well

Use this to compare medications and set expectations, then track reality against it with the weight-loss percentage calculator once you start. If the numbers make a GLP-1 feel worth exploring, the next questions are whether you qualify and how to get one — a licensed provider decides what’s appropriate for you. This tool is educational and not medical advice.

FAQ

Common questions

How much weight can you lose on a GLP-1?

In the pivotal trials, average total body-weight loss ran from about 8% on liraglutide (Saxenda) to about 15% on semaglutide 2.4 mg (Wegovy) and about 21% on tirzepatide 15 mg (Zepbound), over roughly 56–72 weeks with diet and exercise. For a 220 lb person that's roughly 18 to 46 lb depending on the drug. Individual results vary widely.

How is this estimate calculated?

It multiplies your current weight by the average percentage of body weight lost in that drug's main clinical trial (for example SURMOUNT-1 for tirzepatide, STEP 1 for semaglutide). The range shows where most trial participants landed. It's a trial-average projection, not a personalized prediction.

Why is the Ozempic estimate lower than Wegovy if they're the same drug?

They're both semaglutide, but at different doses studied in different trials. Wegovy uses the higher 2.4 mg dose in obesity trials; Ozempic's figures come from lower-dose diabetes trials, where average weight loss is smaller. That's why Ozempic and Mounjaro (both technically off-label for weight loss) show more conservative numbers here.

Will I actually lose this much?

Maybe more, maybe less. These are averages — in the trials, some people lost far more than the average and some lost little. Your result depends on your dose, how long you stay on it, diet, activity, sleep, and individual biology. Reaching the higher doses and staying consistent are the biggest levers.

Sources

What this is based on

  1. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — New England Journal of Medicine
  2. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — New England Journal of Medicine
  3. Liraglutide 3.0 mg for Weight Management (SCALE Obesity and Prediabetes) — New England Journal of Medicine

This tool is for general education only and is not medical advice. Results are estimates based on the numbers you enter and published clinical averages; individual results vary. Talk to a licensed healthcare provider about your own situation. Medical disclaimer

Find the right GLP‑1 in 2 minutes

Free · No account · Independent